Related Experiment Videos
[Diagnosis of deficiency in cofactor of phenylalanine hydroxylase: a metabolic emergency]
M Meyer1, G Malpuech, J Geneste
1Clinique Médicale Infantile B, Hôtel Dieu, Clermont-Ferrand.
Insights
Early diagnosis and treatment of biopterin synthetase deficiency with biopterin and neurotransmitters are crucial for normal neurologic development. Delayed treatment can lead to mental deficiency and dystonia.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Neurology
Background:
- Biopterin synthetase deficiency is a rare metabolic disorder affecting neurotransmitter synthesis.
- Early diagnosis and intervention are critical for managing genetic conditions.
Observation:
- Two children with biopterin synthetase deficiency were treated with biopterin and neurotransmitters (6-hydroxytryptophan and dihydrophenylalanine).
- One child diagnosed and treated early exhibited normal neurologic development.
- The second child, treated from 7 months old, developed mental deficiency and dystonia, possibly linked to Levodopa treatment.
Findings:
- Timely treatment initiation significantly impacts neurodevelopmental outcomes in biopterin synthetase deficiency.
- Neurotransmitter supplementation is a key therapeutic strategy, but potential side effects require monitoring.
Implications:
- This study highlights the importance of prompt diagnosis and treatment for preventing severe neurological complications in biopterin synthetase deficiency.
- Further research is needed to optimize neurotransmitter therapy and manage potential long-term complications.
Abstract:
We report on two cases of children suffering from biopterin synthetase deficiency. Both were treated with the same treatment schedule with biopterin and neurotransmitters: 6-hydroxytryptophan and dihydrophenylalanine (DOPA). The only difference between the two cases is the time of diagnosis and therefore of treatment. The child who was treated early has a normal neurologic development. The other one has been treated since he was 7 months old and is mentally deficient (DQ = 0.60). This older child also suffers from dystonia probably secondary to Levodopa treatment. The authors emphasize the uncertainty of these patient's evolution owing to complications of the disease itself or those due to prolonged treatment by neurotransmitters.